Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging Study of GSK573719 + Fluticasone Furoate in Asthma
NCT01573624Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in asthma (3 arms), sponsored by GSK. Primary endpoints: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second at Day 15, Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response at Day 15 and 1 more. Started Apr 2012; status: completed.
02
Drugs
umeclidinium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01573624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573624.